Longeveron (LGVN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

LGVN Longeveron

Watchlist

2.040
+0.040+2.00%

Trading Nov 27 13:45 ET

30.27MMarket Cap-362P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate
Yahoo FinanceNov 15 06:43 ET
Express News | Watching Longeveron; Zacks Small-Cap Research Sets $9.50 Price Valuation
BenzingaNov 13 10:00 ET
Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript Summary
moomoo AINov 12 22:59 ET · Conference Call
Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript
Earnings Call TranscriptsNov 12 22:37 ET
Longeveron | 10-Q: Q3 2024 Earnings Report
SECNov 12 16:46 ET · Announcements
Longeveron 3Q Loss/Shr 34c >LGVN
Dow JonesNov 12 16:39 ET

Comments

GoldenRam

Nov 26 04:42

$Longeveron (LGVN.US)$ is the drug or whatever they are producing coming onto the market soon ? i got in because of their alzheimer stuff. is that on track? brandon already about to check into a home.

Clintzilla

Nov 25 09:38

$Longeveron (LGVN.US)$ creeper creeper

Teddy123

Nov 25 06:14

Longeveron Buy Rating Affirmed: Promising Clinical Developments and Strong Financial Position

$Longeveron (LGVN.US)$

In Faith We Trust

Nov 20 11:01

$Longeveron (LGVN.US)$ Fxxx stock. loose so much

103673643

Nov 18 17:43

$Longeveron (LGVN.US)$
Longeveron Reports Positive FDA Type C Meeting on BLA Pathway for Lomecel-B in HLHS
The Phase 2B trial for the CLEAR MIND study, which evaluates Lomecel-B for mild Alzheimer's disease, is anticipated to start following a meeting with the FDA before the end of 2024. This meeting aims to outline the future clinical and regulatory strategy for Lomecel-B, based on the positive results from the Phase 2A trial. Specific timelines for initiating the Phase 2B trial will depend on t...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

LGVN Longeveron

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target